Cancer trial information sheets are their own worst enemies, says study

Cancer trial information sheets--the leaflets used to inform potential participants in a cancer clinical trial-- are shooting themselves in the foot, according to research published in the journal Sociology of Health and Illness.

Instead of encouraging participation among potential patients, these information sheets that give the participant much of the required information needed before committing to a clinical trial are "far too long, incomprehensible and ... intimidating."

Ultimately many patients barely read it and instead turn to their doctor or health care professionals to discuss the issue.

Researchers determined that these information sheets are missing the mark; they aren't speaking to the needs of the patients for as much understandable information as possible without being overwhelmed, nor are they written in non-jargon that's understandable. Rather, patients say that they're written like legal forms that go above and beyond to protect the doctors and clinics from legal problems.

The UK's Health Research Authority (HRA) commented on the study, saying that body "recognizes the evident dissatisfaction around participant information sheets. It is currently rewriting guidance that will focus on key principles rather than proscriptive instruction. It will work with public, patients, researchers and others involved in regulation and governance of research to look at all aspects of seeking consent, beyond the written information provided. We will support our work with evidence and consensus (where it exists) from the fields of research, ethics and decision-making."

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap